Iridex reports 47% increase in third-quarter revenue

MOUNTAIN VIEW, Calif. — Third-quarter revenue for Iridex increased 47% to $13.6 million, the company announced in a press release.

Specifically, third-quarter ophthalmology sales totaled $7.9 million, and aesthetics sales totaled $5.7 million, according to the release.

Also during the third quarter, domestic sales increased 26% to $7.2 million, and international sales increased 80% to $6.4 million, both compared with the same period last year.

The company's net loss totaled $1.2 million, or $0.15 per diluted share, in the third quarter.

For the first 9 months of the year, revenue totaled $41.4 million, compared with $26.9 million for the same period last year. The 9-month net loss was $6.5 million, or $0.80 per diluted share, compared with a net loss of $2 million, or $0.26 per diluted share, for the same period of 2006.

"This has been a difficult year for Iridex, our employees and our shareholders. We have and will continue to take decisive actions to improve operations, to provide value to our customers and to create value for our shareholders," said Theodore A. Boutacoff, Iridex president and CEO, in the release. "A key area of focus will be addressing remaining issues and challenges relating to our expanded aesthetics business following the Laserscope acquisition."